Read the latest reports on Western Europe, with local insight, sp...
Read the latest reports on Western Europe, with local insight, specialist knowledge and a comprehensive breakdown of key market data. Our research identifies key strategic themes relevant across the region, while also providing a more granular unders...
Healthy growth in dermatologicals is stemming from launches of value-added products. There was a pause on most new product development activity during the COVID-19 crisis, but with the end of the pandemic, products that had been held back have been…
Dermatologicals is expected to register an increase in current value sales in 2023, partly as a result of the energy crisis stemming from the war in Ukraine, which is pushing up retail prices.
Sales of dermatologicals strongly rely on consumers visiting pharmacies (the dominant distribution channel) as Belgians rarely go first to these stores specifically to purchase such products. Instead these are generally secondary purchases alongside…
Dermatologicals is seeing mid-single digit growth in current value terms in 2023, although like many areas of consumer health this is largely the result of price increases. Prices have been rising across all categories of dermatologicals as a result…
Manufacturers have raised their prices due to the rising costs of energy, raw materials, production and logistics amid a highly inflationary climate. Nonetheless, in many cases, consumers have continued to buy the more expensive branded options as…
Current value sales of cough, cold and allergy (hay fever) remedies rebounded to pre-pandemic levels in 2022 as the UK experienced its strongest cold and flu season in recent years, as a result of greater socialising as restrictions eased, thereby…
Cough, cold, and allergy (hay fever) remedies is projected to continue to post retail current value growth in 2023, following a severe decline in 2020 due to the Coronavirus (COVID-19) pandemic. Having passed the 2019 pre-pandemic level in 2022, the…
Cough, cold and allergy (hay fever) remedies have witnessed stronger growth in 2023, due to warmer weathers and increased time spent out of the home. Warmer weather in Switzerland has led to an increase in pollen and the incidence of allergic…
Cough, cold and allergy (hay fever) remedies remained the largest product area within consumer health in Sweden in 2023. Following a two-year period of buoyant volume growth for most subcategories, demand weakened significantly in 2023, This was due…
After the surge in sales that cough, cold and allergy (hay fever) remedies experienced in 2022, demand is waning in 2023, with the category recording more subdued growth rates. Traditionally, sales of cough, cold and allergy (hay fever) remedies in…
During the winters 2020/2021 and 2021/2022, the circulation of cough, cold and flu viruses was limited by the restrictions implemented to contain the COVID-19 pandemic. Winter 2022/2023 was the first one with no restrictions in place at all and this…
Cough, cold and allergy (hay fever) remedies remains the largest OTC category in Norway, accounting for more than one-third of total OTC value sales in 2023. Despite the already relatively high penetration of these products, the category registered…
Cough/cold remedies are set to see high single-digit growth in current value terms in 2023, with sales likely to benefit from a high number of cases of cold and flu in the 2023/2024 season. Furthermore, value sales will likely also be boosted by unit…
Cough, cold and allergy (hay fever) remedies are enjoying strong growth in 2023 as the category continues to recover from the sharp declines seen during the COVID-19 pandemic. Flu, common coughs and colds and seasonal allergies in the Irish…
In May 2022, Greece lifted all COVID-19 related regulations. This included the compulsory use of face masks and social distancing rules, and although use of face masks remains fairly high in Greece compared to other European countries, it appears…
Cough and cold remedies were recording see high single-digit growth in current value terms in 2023, with sales benefiting from the large number of cases of cold and flu in the 2023/2024 season. Furthermore, value sales were also being boosted by unit…
Within OTC consumer health in France, value sales of cough, cold and allergy (hay fever) remedies are continuing to record the fastest growth in 2023, following a dynamic performance the previous year. Within the category, demand for various formats…
Cough, cold and allergy (hay fever) sales are expected to be slightly down in 2023. This is partly a result of the very strong performance seen in the previous year, as the lifting of COVID-19 related restrictions led to greater social contact and…
Cough remedies and decongestants, which had seen strong growth during the pandemic period, saw more moderate growth in 2022 and 2023 as the contagion receded and public concern waned. Current value sales growth partly reflects inflationary pressures,…
Sales of cough, cold and allergy (hay fever) remedies are seeing strong growth in current value terms in 2023. This is partly due to inflation-driven price increases (also the consequence of supply shortages in some cases) and an increase in cough,…